These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21349929)

  • 1. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis.
    Phung OJ; Kahn SR; Cook DJ; Murad MH
    Chest; 2011 Aug; 140(2):374-381. PubMed ID: 21349929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing.
    Mahan CE; Pini M; Spyropoulos AC
    Intern Emerg Med; 2010 Aug; 5(4):299-306. PubMed ID: 20177819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction).
    Alikhan R; Bedenis R; Cohen AT
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD003747. PubMed ID: 24804622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
    Akl EA; Labedi N; Terrenato I; Barba M; Sperati F; Sempos EV; Muti P; Cook D; Schünemann H
    Cochrane Database Syst Rev; 2011 Nov; (11):CD009447. PubMed ID: 22071865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unfractionated Heparin TID Dosing Regimen Is Associated With a Lower Rate of Pulmonary Embolism When Compared With BID Dosing in Patients Undergoing Craniotomy.
    Thirunavu V; Kandula V; Shah P; Yerneni K; Karras CL; Abecassis ZA; Bloch O; Potts M; Jahromi B; Tate MC
    World Neurosurg; 2021 Sep; 153():e147-e152. PubMed ID: 34166830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
    Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
    J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Dongen CJ; van den Belt AG; Prins MH; Lensing AW
    Cochrane Database Syst Rev; 2004 Oct; (4):CD001100. PubMed ID: 15495007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis.
    King CS; Holley AB; Jackson JL; Shorr AF; Moores LK
    Chest; 2007 Feb; 131(2):507-16. PubMed ID: 17296655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Vardi M; Zittan E; Bitterman H
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006771. PubMed ID: 19821386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis.
    Beitland S; Sandven I; Kjærvik LK; Sandset PM; Sunde K; Eken T
    Intensive Care Med; 2015 Jul; 41(7):1209-19. PubMed ID: 25971389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
    Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
    Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    Erkens PM; Prins MH
    Cochrane Database Syst Rev; 2010 Sep; (9):CD001100. PubMed ID: 20824828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.
    Spyropoulos AC; Turpie AG; Dunn AS; Spandorfer J; Douketis J; Jacobson A; Frost FJ;
    J Thromb Haemost; 2006 Jun; 4(6):1246-52. PubMed ID: 16706967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
    Wilbur K; Lynd LD; Sadatsafavi M
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):454-65. PubMed ID: 20699258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and Mechanical Thromboprophylaxis in Critically Ill Patients: a Network Meta-Analysis of 12 Trials.
    Park J; Lee JM; Lee JS; Cho YJ
    J Korean Med Sci; 2016 Nov; 31(11):1828-1837. PubMed ID: 27709864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse relationship of bleeding risk with clot burden during pulmonary embolism treatment with LMW heparin.
    Wang C; Zhai Z; Yang Y; Cheng Z; Ying K; Liang L; Dai H; Huang K; Lu W; Zhang Z; Cheng X; Shen YH; Davidson BL;
    Clin Respir J; 2016 Sep; 10(5):596-605. PubMed ID: 25619125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.